Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) - Equities research analysts at William Blair reduced their FY2026 earnings per share estimates for shares of Telix Pharmaceuticals Limited American Depositary Shares in a research report issued on Monday, April 28th. William Blair analyst A. Hsieh now anticipates that the company will earn $1.03 per share for the year, down from their previous estimate of $1.05. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Telix Pharmaceuticals Limited American Depositary Shares' current full-year earnings is $0.24 per share. William Blair also issued estimates for Telix Pharmaceuticals Limited American Depositary Shares' FY2027 earnings at $1.40 EPS.
Separately, UBS Group boosted their price objective on shares of Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Monday, January 27th.
Check Out Our Latest Analysis on Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited American Depositary Shares Stock Up 4.2 %
TLX traded up $0.76 on Tuesday, reaching $18.70. The company's stock had a trading volume of 45,250 shares, compared to its average volume of 27,794. Telix Pharmaceuticals Limited American Depositary Shares has a fifty-two week low of $13.61 and a fifty-two week high of $30.36. The business has a 50 day simple moving average of $17.18.
About Telix Pharmaceuticals Limited American Depositary Shares
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
See Also
Before you consider Telix Pharmaceuticals Limited American Depositary Shares, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals Limited American Depositary Shares wasn't on the list.
While Telix Pharmaceuticals Limited American Depositary Shares currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
